Iván Cavero-Redondo

Iván Cavero-Redondo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
IOIris Otero-Luis
Iris Otero-Luis
AMArturo Martinez-Rodrigo
Arturo Martinez-Rodrigo
ICIván Cavero-Redondo
Iván Cavero-Redondo
NMNerea Moreno-Herraiz
Nerea Moreno-Herraiz
Irene Martínez GarcíaIrene Martínez García
Irene Martínez García
ASAlicia Saz-Lara
Alicia Saz-Lara
Background: Spasticity is a very common neurological sequelae that significantly impacts the quality of life of patients, affecting more than 12 million people worldwide. Botulinum toxin is considered a reversible treatment for spasticity, but due to the large amount of available evidence, synthesis seems necessary. Therefore, we conducted an overview of existing systematic reviews and meta-analyses to evaluate the effect of botulinum toxin injections in the treatment of spasticity of different etiologies. Methods: A systematic search of different databases, including Pubmed, Scopus, the Cochrane Library, and Web of Science, was performed from inception to February 2024. Standardized mean differences (SMDs) and their respective 95% confidence intervals (CIs) were calculated to assess the effect of botulinum toxin compared to that of the control treatment using the Modified Ashworth Scale (MAS). All the statistical analyses were performed using STATA 15 software. Results: 28 studies were included in the umbrella review. The effect of botulinum toxin injections on spasticity, as measured by the MAS, was significantly lower in all but three studies, although these studies also supported the intervention. The SMDs reported by the meta-analyses ranged from −0.98 to −0.01. Conclusion: Botulinum toxin injections were effective at treating spasticity of different etiologies, as indicated by the measurements on the MAS. This implies an improvement in muscle tone and, consequently, in the patient’s mobility and quality of life.

1 June 2025 in Journal of neurosurgery. Pediatrics
Verified
Journal Article
Closed access
PDF file
IOIris Otero-Luis
Iris Otero-Luis
AMArturo Martinez-Rodrigo
Arturo Martinez-Rodrigo
ICIván Cavero-Redondo
Iván Cavero-Redondo
NMNerea Moreno-Herráiz
Nerea Moreno-Herráiz
FAFelipe Araya-Quintanilla
Felipe Araya-Quintanilla
ASAlicia Saz-Lara
Alicia Saz-Lara
OBJECTIVE: Spasticity is one of the most prevalent neurological disorders, affecting > 90% of patients with cerebral palsy (CP). Selective dorsal rhizotomy (SDR) is a permanent neurosurgical procedure indicated for the treatment of spasticity. This study aimed to analyze the efficacy of SDR in managing spasticity in children with CP and as well as the efficacy of this therapy over time after the intervention using different scales. METHODS: A comprehensive systematic search was conducted across several databases, spanning from inception to November 5, 2023. Random-effects meta-analyses were used to calculate pooled mean differences and their corresponding confidence intervals to assess the efficacy of SDR using different scales. RESULTS: All the included studies involved before-after single-arm studies, with the exception of four randomized clinical trials and one quasi-experimental study. The effect of SDR on spasticity, measured with the modified Ashworth scale (MAS) and the Gross Motor Function Measure (GMFM), was significantly improved in children with lower limb spasticity. The efficacy of the treatment was significant up to 12 months posttreatment. CONCLUSIONS: SDR has been demonstrated to be effective in treating children with CP. This efficacy is evidenced by notable improvements, as measured by both the MAS and GMFM. These improvements suggested enhanced mobility and overall quality of life.

30 September 2024 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
IOIris Otero-Luis
Iris Otero-Luis
AMArturo Martínez-Rodrigo
Arturo Martínez-Rodrigo
ICIván Cavero-Redondo
Iván Cavero-Redondo
NMNerea Moreno-Herráiz
Nerea Moreno-Herráiz
SLSamuel López-López
Samuel López-López
ASAlicia Saz-Lara
Alicia Saz-Lara
Spasticity, a prevalent manifestation of various neurological conditions, significantly impacts the quality of life of patients. Research on the effects of oral drugs on spasticity has produced controversial results. Thus, the aim of this network meta-analysis was to compare the efficacy of oral drugs for improving spasticity in patients with different etiologies. We searched four different databases from their inception to 30 November 2023. A network meta-analysis using a frequentist perspective was conducted to assess the effects of different oral drugs on spasticity, evaluated by the modified Ashworth scale. Our findings showed that, in a frequentist network meta-analysis, eperisone, diazepam, and baclofen had significantly greater spasticity, as measured by the modified Ashworth scale, than did the placebo (MD: −0.80; 95% CIs: −1.42, −0.18; MD: −0.68; 95% CIs: −1.28, −0.09; MD: −0.58; 95% CIs: −1.11, −0.06, respectively). In summary, our study confirmed that eperisone, diazepam, and baclofen could be effective approaches for reducing spasticity of different etiologies and could be useful approaches for improving patient quality of life. What is already known on this topic: The impact of oral drugs, such as baclofen, gabapentin, tizanidine, and dantrolene, in the treatment of spasticity has been documented. What this study adds: This study determines which of the oral drugs aimed at treating spasticity is the most effective across different etiologies. How this study might affect research, practice, or policy: This study suggests tailored treatment strategies for spasticity based on its etiology.